PTJ
HUMA icon

Paul Tudor Jones’s Humacyte HUMA Stock Holding History

Paul Tudor Jones’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-157,300
Closed -$274K – 3718
2025
Q3 		$274K Buy
+157,300
New +$308K ﹤0.01% 3034

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's HUMA Position: Q2 2026 in Review

Paul Tudor Jones held its Humacyte (HUMA) position steady in Q2 2026 at 12,300 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3454.

Paul Tudor Jones first reported a position in HUMA in Q4 2020 and has held it in 6 quarters since. The position peaked at $5.88M in Q1 2021. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Paul Tudor Jones held 12,300 shares of Humacyte worth $9.6K as of Q2 2026.
  • Paul Tudor Jones left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3454 holding.
  • Paul Tudor Jones first reported a position in Humacyte in Q4 2020 and has held it in 6 quarters since.
  • Paul Tudor Jones's Humacyte position peaked at $5.88M in Q1 2021.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.